June 2021 Vol 7 No 3
After a breast cancer diagnosis and blocking her positive energy for too long, Constance Drake turned to painting to release healthy energy through art. Read More ›
Kimberley Norris relates her experience as a bedside advocate for her husband, Rick, after his esophageal cancer diagnosis, introducing her discussion of the challenges of advocating for a hospitalized patient with cancer. Read More ›
George Valentine was diagnosed with chronic lymphocytic leukemia in 2002. He shares some of his hard-learned tips on how to deal with a cancer diagnosis and the high costs of treatment. Read More ›
By Wayne Kuznar
HPV infection is the most common sexually transmitted disease and the cause of several types of cancer, including anal cancer. Several experts explain the effectiveness of the HPV vaccine in preventing these cancers, something that we should all be aware of. Read More ›
Jennifer Reginald chronicles how nagging headaches turned into a brain tumor diagnosis, and how she had different tumors removed on the same day, twice, but 32 years apart. Read More ›
Meg Cadoux Hirshberg, co-founder of the Anticancer Lifestyle Program that promotes mindful living, describes different stress-reduction techniques, types of meditation, and other practical tools used for stress reduction. Read More ›
After spending many nights in pain, unable to breathe, Kayla Sanderson was told that the lump in her neck was “nothing” but a bad ear infection. Finally, she found out a tumor was blocking her airways. Read More ›
Carly Gerretsen, DNP, RN, FNP-C, RNFA, provides an overview of kidney cancer, explaining the various stages of a kidney cancer diagnosis, symptoms, treatment options, caregiver’s assistance, and stress management advice. Read More ›
In March 2021, the FDA approved Lorbrena (lorlatinib), a third-generation ALK inhibitor, for first-line treatment of patients with non–small-cell lung cancer and ALK mutation. Lorbrena was previously approved for the second- or third-line treatment for this patient population. Read More ›
In February 2021, the FDA approved Cosela (trilaciclib) as the first CDK4/6 inhibitor to reduce the risk of chemotherapy-induced myelosuppression in adults with extensive-stage small-cell lung cancer. Cosela can prevent damage to bone marrow cells by blocking the CDK4/6 enzyme. Read More ›